Ozempic & GLP-1 Lawsuit in California

GLP-1 receptor agonist medications — including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, and Trulicity — were prescribed to millions of California residents for type 2 diabetes and weight management. While these drugs were marketed as breakthrough treatments, growing evidence has linked them to severe and sometimes permanent injuries that the manufacturers allegedly failed to adequately disclose.

The federal litigation against Novo Nordisk and Eli Lilly has been consolidated into multidistrict litigation (MDL 3094) in the Eastern District of Pennsylvania. California residents who suffered injuries from GLP-1 medications can file claims that join this consolidated proceeding, benefiting from coordinated pretrial discovery while retaining their individual right to trial.

The lawsuits allege that the manufacturers knew their drugs could cause serious gastrointestinal injuries — including stomach paralysis, bowel blockages, and pancreatic inflammation — as well as vision loss, yet they prioritized profits over patient safety by failing to warn prescribers and patients about the true scope of these risks. For California residents, the stakes are high: these injuries can be permanent, require multiple surgeries, and fundamentally alter quality of life.

As the litigation progresses, early bellwether trials are expected to set the stage for broader settlement discussions. California residents who have been injured should evaluate their claims now, before filing deadlines expire.

California legal landscape: California follows strict liability for defective products, meaning plaintiffs do not need to prove negligence. The state also applies pure comparative fault, so recovery is not barred even if the plaintiff shares some responsibility. Residents in Los Angeles, San Francisco, San Diego, San Jose, and Sacramento and surrounding areas should consult with an attorney experienced in pharmaceutical litigation to evaluate their potential claim.